Eiger BioPharmaceuticals, Inc.
EIGRDelisted Apr 25, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001305253
Eiger BioPharmaceuticals, Inc. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Nov 2, 2023; 43 institutions reported holding it in 13F filings for Q4 2023, worth $4.16M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Eiger BioPharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Eiger BioPharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kayne Richard A | 10% Owner | 5,375,225Indirect | Nov 2, 2023 | 0 |
| Kawas Leen | 10% Owner | 4,391,432Indirect | Nov 2, 2023 | 0 |
| Choong Ingrid | Chief Business Officer | – | Sep 5, 2023 | 0 |
| Apelian David | CEO | 11,000 | Jul 6, 2023 | 0 |
| Vollins James | General Counsel | – | May 2, 2023 | 0 |
| Mayer Eldon C. III | Ex VP & Chief Commerc. Officer | 56,073 | Mar 21, 2023 | 0 |
| Sachdev Amit | Director | 16,000 | Mar 3, 2023 | 0 |
| Dietz Thomas John | Director | 50,000Indirect | Mar 3, 2023 | 0 |
| Murray Christine | Director | 11,000 | Mar 3, 2023 | 0 |
| Loh Evan | Director | 14,000 | Mar 3, 2023 | 0 |
| Glenn Jeffrey S | Director | 182,355 | Mar 3, 2023 | 0 |
| Sablich Kim | Director | 6,000 | Mar 3, 2023 | 0 |
| Kelly-Croswell Lisa | Director | – | Mar 3, 2023 | 0 |
| Atkisson Erik | GC & Chief Compliance Officer | 6,000 | Jan 30, 2023 | 0 |
| Ryali Sriram | Chief Financial Officer | 41,566 | Mar 14, 2022 | 0 |
| Cory David A | President and CEO | 169,183 | Mar 11, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 2, 2023 (view filing)9:21 PM ET | Oct 31-Nov 2 | 2 days | Kayne Richard A10% Owner | PPurchase | +278.2K | $0.2617 | +$72.8K | +5.5%5.38M after | 5 lots |
| Nov 2, 2023 (view filing)9:14 PM ET | Oct 31 | 2 days | Kawas Leen10% Owner | PPurchase | +24.3K | $0.262 | +$6.37K | +0.6%4.39M after | 2 lots |
| Mar 21, 2023 (view filing) | Mar 17 | 4 days | Mayer Eldon C. IIIEx VP & Chief Commerc. Officer | SSale | −4.39K | $1.07 | −$4.70K | −7.3%56.1K after | 2 lots |
| Jan 25, 2023 (view filing) | Jan 23 | 2 days | Dietz Thomas JohnDirector | PPurchase | +50.0K | $1.43 | +$71.5K | New position50.0K after | |
| Jan 3, 2023 (view filing) | Dec 29, 2022 | 5 days | Murray ChristineDirector | SSale | −5.00K | $1.22 | −$6.10K | −31.3%11.0K after | |
| Dec 27, 2022 (view filing) | Dec 22 | 5 days | Dietz Thomas JohnDirector | SSale | −22.5K | $1.17 | −$26.3K | −51.7%21.0K after | |
| Dec 27, 2022 (view filing) | Dec 22 | 5 days | Glenn Jeffrey SDirector | PPurchase | +100.0K | $1.28 | +$128.0K | +121.4%182.4K after | |
| Aug 18, 2022 (view filing) | Aug 16 | 2 days | Apelian DavidDirector | SSale | −5.00K | $9.81 | −$49.0K | −31.3%11.0K after | |
| Mar 14, 2022 (view filing) | Mar 14 | Same day | Ryali SriramChief Financial Officer | SSale | −2.27K | $5.60 | −$12.7K | −5.2%41.6K after | |
| Mar 14, 2022 (view filing) | Mar 14 | Same day | Mayer Eldon C. IIIEx VP & Chief Commerc. Officer | SSale | −1.66K | $5.60 | −$9.28K | −2.7%60.5K after | |
| Jan 11, 2022 (view filing) | Jan 7 | 4 days | Mayer Eldon C. IIIEx VP & Chief Commerc. Officer | SSale | −1.56K | $4.95 | −$7.72K | −3.3%46.1K after |